October 11th Highlights

  • SAS B numbers for Sept - Roughly 67,000 applications for unapproved medicinal cannabis products have been granted since the beginning of the program. September’s figure is 18% higher than the previous month.
  • Great Government Leadership - The French government published a long-awaited decree this week detailing how a limited medical cannabis experiment will be carried out. It was also confirmed that up to 3,000 patients will be able to participate in the experiment. Participating companies will have to supply the medical cannabis products to patients free of charge, and the products will have to comply with pharmaceutical standards, including Good Manufacturing Practice. This is excellent government thinking - providing access to free cannabis for patients to gather data. This data will allow the government to build an informed access program whilst providing doctor and patient education. You can read more about the access program here.

MediPharm Labs secured a deal with German-based STADA Pharma - one of Europe’s largest pharma companies

Australian Government flags tougher regulations for imported medicinal cannabis products

WHO cannabis recommendations still face uphill battle for adoption

Race is on for synthetic cannabinoids

Australia approves record number of medical cannabis patients

New Zealand extends medical cannabis transition to avoid supply disruption 

Cannabis referendum: Health experts lay out the case for voting 'yes'

Incannex achieves record medicinal cannabis oil sales as pure play pharmaceutical company

Budget report: Federal Government increases medicinal cannabis funding by $1.7 million

Taranaki company making NZ's first CBD and mānuka honey blend